Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docebaxel – three year results of a pilot study

2002 ◽  
Vol 30 (2) ◽  
pp. 112-120 ◽  
Author(s):  
Adorján F. Kovács ◽  
Mirko Schiemann ◽  
Bernd Turowski
Keyword(s):  
Pilot Study ◽  
Oropharyngeal Cancer ◽  
Radical Surgery ◽  
Combined Modality Treatment ◽  
Combined Modality ◽  
Oral And Oropharyngeal Cancer

Effects of jaw exercise intervention timing on outcomes following oral and oropharyngeal cancer surgery: Pilot study

Head & Neck ◽  
2019 ◽  
Vol 41 (11) ◽  
pp. 3806-3817
Author(s):  
Mykayla L. Sandler ◽  
Cathy L. Lazarus ◽  
Meng Ru ◽  
Kayvon F. Sharif ◽  
Lauren E. Yue ◽  
...  
Keyword(s):  
Pilot Study ◽  
Oropharyngeal Cancer ◽  
Exercise Intervention ◽  
Cancer Surgery ◽  
Oral And Oropharyngeal Cancer

Survival of patients with oligometastatic pancreatic ductal adenomacarcinoma treated with combined modality treatment including surgical resection: A pilot study.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e15690-e15690
Author(s):  
Pujan Kandel ◽  
Kabir Mody ◽  
Horacio Asbun ◽  
John Stauffer ◽  
Candice W Bolan ◽  
...  
Keyword(s):  
Pilot Study ◽  
Surgical Resection ◽  
Combined Modality Treatment ◽  
Combined Modality

e‐Health self‐management intervention for oral and oropharyngeal cancer survivors: design and single‐arm pilot study of empowered survivor

Head & Neck ◽  
2020 ◽  
Vol 42 (11) ◽  
pp. 3375-3388 ◽  
Author(s):  
Sharon Manne ◽  
Shawna Hudson ◽  
Sara Frederick ◽  
Anna Mitarotondo ◽  
Soly Baredes ◽  
...  
Keyword(s):  
Pilot Study ◽  
Cancer Survivors ◽  
Oropharyngeal Cancer ◽  
Self Management ◽  
Management Intervention ◽  
Oral And Oropharyngeal Cancer

scholarly journals Immediate results of radical surgery under conditions of combined modality treatment of rectal cancer

2016 ◽  
Vol 15 (1) ◽  
pp. 5-10 ◽  
Author(s):  
S.G. Afanasyev ◽  
◽  
Zh.А. Startseva ◽  
А.Yu. Dobrodeev ◽  
А.S. Tarasova ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Radical Surgery ◽  
Combined Modality Treatment ◽  
Combined Modality

Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4779-4779
Author(s):  
Ranjana H. Advani ◽  
Hailun Li ◽  
Richard T. Hoppe ◽  
Nancy L. Bartlett ◽  
John M. Bennett ◽  
...  
Keyword(s):  
Pilot Study ◽  
Eastern Cooperative Oncology Group ◽  
Combined Modality Treatment ◽  
Cell Transplant ◽  
Primary Therapy ◽  
Second Cancer ◽  
Oncology Group ◽  
Second Cancers ◽  
Combined Modality

Abstract Abstract 4779 Purpose: The Stanford V regimen is a combined modality approach for treatment of Hodgkin lymphoma (HL). E1492, an ECOG pilot study, consisted of 12 weeks of Stanford V chemotherapy followed by 36 Gy radiation therapy (RT) to sites > 5 cm or macroscropic splenic disease at diagnosis. Efficacy results were reported previously (Horning et al. J Clin Onc 18, 2000). The study now has a median follow up of 17 years and patients have been followed for overall survival (OS) and development of second cancers. Methods: 47 eligible patients with stage bulky mediastinal (mass > one third of the maximum intrathoracic diameter) stage I-II or stage III-IV HL were enrolled between March 1992 and February 1995. Patients were followed every 3 months during the first year off therapy, every 6 months during years 2–5 and annually thereafter. The ECOG database was reviewed for OS and reported second cancers. Patient characteristics at baseline, type of second cancer and time to development of second cancer were assessed. RT summary forms were reviewed for patients with second cancers. Results: 41 patients were treated with combined modality therapy and 6 with chemotherapy alone. The median age was 32 years (range 20–56 years). The 5 and 10 year OS are 96%, and 89% respectively. Seven second cancers were reported, as shown in the Table. The cumulative incidence for second cancers accounting for death as a competing risk is 0.02 (95% CI, 0–0.06) at 5 years, 0.07 (95% CI, 0–0.14) at 10 years, and 0.15 (95% CI, 0.04–0.27) at 15 years. Complete details of the exact location, histologic subtype and subsequent management of second cancers were not available for review. Five of the 7 cancers [2 skin, 1 prostate, 2 acute myeloid leukemia (AML)] were not radiation-related. One patient developed AML after primary therapy as reported in the initial publication. A second patient developed AML 5 years after salvage therapy followed by autologous stem cell transplant for relapsed HL. It is likely the 2 cases of breast cancer were treatment related. Conclusion: Within the caveats of a retrospective analysis from a small cooperative group phase 2 trial, the mature 10 year OS of 89% and low frequency of secondary cancers are encouraging in comparison to historic treatment with combined modality treatment. Longer follow up of other Stanford V regimen data sets (i.e. United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 and the Eastern Cooperative Oncology Group E2496) are required to confirm these findings. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document